Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs Veritone Inc (VERI) Price & Performance

Incyte CorporationTrade
Veritone IncTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Veritone Inc — how do they compare? Incyte Corporation trades at $120.81 (market cap $24.54B), while Veritone Inc trades at $1.49 (market cap $138.04M). The key difference: Incyte Corporation is far larger — about 177.8× Veritone Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.

INCYVERI
Market Cap
$24.54B$138.04M
Sector
HealthTechnology
52-Week High
$129.93$8.39
52-Week Low
$81.61$1.00
Enterprise Value
$20.04B$170.07M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.

Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.

Veritone Inc

Veritone (VERI) trades at $1.53, up 6.25% in 24 hours, with a bullish technical signal from moving averages and ADX indicators. The company reported revenue of $92.19M in 2025 but a net loss of $111.73M, reflecting negative profit margins and ROE. Recent news highlights partnerships with ZeroEyes and the Department of Energy, though a securities class action lawsuit was filed in July 2026 over alleged accounting issues.

The outlook is mixed: analyst consensus leans neutral with 46% buy ratings, but persistent losses and legal risks pose challenges. Upside hinges on AI partnership growth improving profitability, while downside risks include ongoing cash burn and litigation uncertainties. Investors should weigh growth potential against financial stability concerns.

Returns comparison

Trailing returns across standard periods

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About Veritone Inc

Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.

Read more on VERI